RNA-directed RNA polymerase L · SINGLE PROTEIN · Human respiratory syncytial virus A
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14RNA-directed RNA polymerase L shows clinical signal disease relevance led by Respiratory Syncytial Virus Infection. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P28887. Start with Respiratory Syncytial Virus Infection, then reuse UniProt P28887 as the stable protein anchor across project notes and exports.
Start with Respiratory Syncytial Virus Infection, then reuse UniProt P28887 as the stable protein anchor across project notes and exports.
RNA-directed RNA polymerase L shows clinical signal disease relevance led by Respiratory Syncytial Virus Infection. 2 linked drugs remain visible in the same block.
Start review with Respiratory Syncytial Virus Infection because it currently carries clinical signal support. Linked drugs include LUMICITABINE, PC-786. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyRNA-directed RNA polymerase L
Review this target as RNA-directed RNA polymerase L, mapped to UniProt P28887. Sequence length is 2165 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats RNA-directed RNA polymerase L as ChEMBL target CHEMBL4630897, mapped to UniProt P28887. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether RNA-directed RNA polymerase L is the right protein anchor across sources, using UniProt P28887 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why Respiratory Syncytial Virus Infection is currently framed as clinical signal support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | RNA-directed RNA polymerase L |
| Target Type | SINGLE PROTEIN |
| Organism | Human respiratory syncytial virus A |
| UniProt | P28887 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | RNA-directed RNA polymerase L |
| UniProt Accession | P28887 |
| Component Type | Protein |
| Sequence Length | 2165 aa |
RNA-directed RNA polymerase L
Review this target as RNA-directed RNA polymerase L, mapped to UniProt P28887. Sequence length is 2165 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
RNA-directed RNA polymerase L shows clinical signal disease relevance led by Respiratory Syncytial Virus Infection.
Start review with Respiratory Syncytial Virus Infection because it currently carries clinical signal support. Linked drugs include LUMICITABINE, PC-786. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.